What Happened?
, -based ImmunoGen Promoted Brenda Som as Associate Director of Total Rewards
Date of management change: May 12, 2022
, -based ImmunoGen Promoted Brenda Som as Associate Director of Total Rewards
Targeting a better life for people with cancer is why we get up in the morning. It`s not enough to disrupt the progress of someone`s cancer; we want to keep cancer from disrupting someone`s life. That`s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives—back to living today, tomorrow, and beyond. Because for us, targeting a better now is the only thing that matters. ImmunoGen is a leader in developing antibody-drug conjugates (ADCs). Our lead product candidate, mirvetuximab soravtansine, is a first-in-class folate receptor alpha (FRα)-targeting ADC with multiple studies underway in ovarian cancer. Our second pivotal program, IMGN632, is a CD123-targeting ADC being studied as a monotherapy in BPDCN and in combination in AML. Our earlier-stage assets in development are IMGC936, an ADAM9-targeting ADC in co-development with MacroGenics, and IMGN151, our next generation anti-folate receptor alpha ADC.
Brenda Som is Associate Director of Total Rewards at ImmunoGen. Previously, Brenda held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Brooks John, Leeper Bud, Horn Janice, Morgan Greg, Deputy Angela, Wilson John, Lewis Kim, Ramanan Venkat, McLaren Ellan, Nghiem Helen, Collins Melanie
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.